Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
| Autor: | Scott R. Solomon, Richard J. O'Reilly, Sergio Giralt, Raquel Palencia, Lori Muffly, Leyla Shune, Miguel-Angel Perales, Brent R. Logan, Mary M. Horowitz, Marcelo C. Pasquini, Nancy L. Geller, Richard J. Jones, Leo Luznik, Adam Mendizabal, Sumithira Vasu, Juan Wu, Johannes Schetelig, Steven M. Devine, Helen E. Heslop, Lynn O'Donnell, Eneida R. Nemecek, Mark R. Litzow, Robert J. Soiffer, Vincent T. Ho |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Time Factors Transplantation Conditioning Adolescent Calcineurin Inhibitors Graft vs Host Disease Disease Disease-Free Survival Tacrolimus Young Adult Recurrence Germany Internal medicine medicine Humans Cyclophosphamide Aged Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation ORIGINAL REPORTS Middle Aged Myeloablative Agonists medicine.disease United States Calcineurin Transplantation Methotrexate Graft-versus-host disease Hematologic Neoplasms Chronic Disease Drug Therapy Combination Female business Immunosuppressive Agents |
| Zdroj: | J Clin Oncol |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PURPOSE Calcineurin inhibitors (CNI) are standard components of graft-versus-host disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data suggested that CNI-free approaches using donor T-cell depletion, either by ex vivo CD34 selection or in vivo post-transplant cyclophosphamide (PTCy) as a single agent, are associated with lower rates of chronic GVHD (cGVHD). METHODS This multicenter phase III trial randomly assigned patients with acute leukemia or myelodysplasia and an HLA-matched donor to receive CD34-selected peripheral blood stem cell, PTCy after a bone marrow (BM) graft, or tacrolimus and methotrexate after BM graft (control). The primary end point was cGVHD (moderate or severe) or relapse-free survival (CRFS). RESULTS Among 346 patients enrolled, 327 received HCT, 300 per protocol. Intent-to-treat rates of 2-year CRFS were 50.6% for CD34 selection (hazard ratio [HR] compared with control, 0.80; 95% CI, 0.56 to 1.15; P = .24), 48.1% for PTCy (HR, 0.86; 0.61 to 1.23; P = .41), and 41.0% for control. Corresponding rates of overall survival were 60.1% (HR, 1.74; 1.09 to 2.80; P = .02), 76.2% (HR, 1.02; 0.60 to 1.72; P = .95), and 76.1%. CD34 selection was associated with lower moderate to severe cGVHD (HR, 0.25; 0.12 to 0.52; P = .02) but higher transplant-related mortality (HR, 2.76; 1.26 to 6.06; P = .01). PTCy was associated with comparable cGVHD and survival outcomes to control, and a trend toward lower disease relapse (HR, 0.52; 0.28 to 0.96; P = .037). CONCLUSION CNI-free interventions as performed herein did not result in superior CRFS compared with tacrolimus and methotrexate with BM. Lower rates of moderate and severe cGVHD did not translate into improved survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|